Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Irinotecan + Selinexor|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Irinotecan||Camptosar||CPT-11|Onivyde||TOPO1 inhibitor 9||Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death and is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov).|
|Selinexor||Xpovio||KPT-330||Xpovio (selinexor) inhibits CRM1 (XPO1), preventing CRM1-mediated nuclear export of tumor suppressor proteins and potentially restoring normal tumor suppressor function (PMID: 30976603, PMID: 31793336). Xpovio (selinexor) is FDA approved for use in patients with diffuse large B cell lymphoma after two or more prior therapies, in combination with Adexone (dexamethasone) in patients with relapsed or refractory multiple myeloma after at least four prior therapies, and in combination with Velcade (bortezomib) and Adexone (dexamethasone) in patients with multiple myeloma after at least one prior therapy (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02283359||Phase I||Irinotecan + Selinexor||Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus||Terminated||USA||0|